Days before embarking on an overseas trip, columnist Sam Kirton makes his final preparations, including getting the OK from his care team.

Rein is working to begin U.K. enrollment for its Phase 2 trial of LTI-03, a candidate therapy for IPF, after receiving ...

Columnist Sam Kirton takes readers on his journey from a pulmonary function test to his results from lung biopsies that weren't routine.

Consistently tracking KL-6 levels may help predict acute exacerbations in IPF and other types of fibrotic ILDs, a study ...

How do you want to be remembered after your passing? Columnist Sam Kirton shares the steps he's taking to leave a positive legacy.

GRI-0621 appears to reduce markers of fibrosis in people with idiopathic pulmonary fibrosis, interim clinical trial data suggest.

Looking for information on Shallow Breathing (Tachypnea) in pulmonary fibrosis? Read about breathing alterations in IPF here.

Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.

GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.

Because certain IPF and post-transplant medications can cause sun sensitivity, skin protection is crucial, says columnist Sam Kirton.